Document is current
Any future updates will be listed below
-
Authors
Hu, Jiemiao https://orcid.org/0000-0002-5142-0641
Lazar, Alexander J
Ingram, Davis
Wang, Wei-Lien
Zhang, Wendong
Jia, Zhiliang
Ragoonanan, Dristhi
Wang, Jian
Xia, Xueqing
Mahadeo, Kris
Gorlick, Richard
Li, Shulin https://orcid.org/0000-0001-5657-4183
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01722149 at ClinicalTrials.govDocuments that mention this clinical trial
Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models
https://doi.org/10.1136/jitc-2023-006991
CARs are sharpening their weapons
https://doi.org/10.1136/jitc-2023-008275
Cancer-associated fibroblast targeting therapies as a tool to enhance responses to radiotherapy and immunotherapy
https://doi.org/10.1136/jitc-2024-009702
-
Funding
Funding for this research was provided by:
NIH (P30 CA016672)
NIH (RO1 CA120985)
- License Information
